ABVC Accounts Payable vs Net Debt Analysis
ABVC Stock | USD 1.42 0.17 10.69% |
ABVC Biopharma financial indicator trend analysis is way more than just evaluating ABVC Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ABVC Biopharma is a good investment. Please check the relationship between ABVC Biopharma Accounts Payable and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
Accounts Payable vs Net Debt
Accounts Payable vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ABVC Biopharma Accounts Payable account and Net Debt. At this time, the significance of the direction appears to have no relationship.
The correlation between ABVC Biopharma's Accounts Payable and Net Debt is 0.06. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Debt in the same time period over historical financial statements of ABVC Biopharma, assuming nothing else is changed. The correlation between historical values of ABVC Biopharma's Accounts Payable and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of ABVC Biopharma are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Accounts Payable i.e., ABVC Biopharma's Accounts Payable and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.06 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents ABVC Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ABVC Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from ABVC Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ABVC Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.As of April 29, 2024, Selling General Administrative is expected to decline to about 5 M. In addition to that, Tax Provision is expected to decline to about 217.9 K
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 11.7M | 16.1M | 8.4M | 4.2M | Total Revenue | 355.8K | 969.8K | 152.4K | 157.4K |
ABVC Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
ABVC Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ABVC Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.9M | 11.6M | 13.7M | 9.9M | 14.9M | 15.7M | |
Short Long Term Debt Total | 4.6M | 6.5M | 3.1M | 3.1M | 2.5M | 1.9M | |
Total Current Liabilities | 6.8M | 4.8M | 3.7M | 5.8M | 5.9M | 6.2M | |
Total Stockholder Equity | (151.0K) | 3.4M | 8.8M | 3.1M | 8.8M | 9.3M | |
Net Debt | 4.4M | 2.2M | (2.7M) | 3.0M | 1.7M | 1.8M | |
Retained Earnings | (15.9M) | (25.6M) | (38.5M) | (54.9M) | (65.4M) | (62.1M) | |
Common Stock Shares Outstanding | 1.7M | 2.0M | 2.5M | 3.2M | 4.3M | 4.6M | |
Liabilities And Stockholders Equity | 6.9M | 11.6M | 13.7M | 9.9M | 14.9M | 15.7M | |
Non Current Liabilities Total | 238.4K | 4.1M | 1.1M | 420.2K | 429.1K | 407.7K | |
Inventory | (477.0K) | (839.7K) | 26.0K | 1.3M | 1.5M | 1.6M | |
Other Stockholder Equity | 15.0M | 28.5M | 46.8M | 57.5M | 73.7M | 77.4M | |
Total Liab | 7.1M | 8.9M | 4.8M | 6.2M | 6.4M | 6.7M | |
Total Current Assets | 878.2K | 6.2M | 9.6M | 3.0M | 1.7M | 1.4M | |
Short Term Debt | 4.3M | 2.4M | 2.0M | 2.3M | 2.0M | 1.4M | |
Other Current Liab | 2.4M | 2.4M | 1.7M | 3.5M | 3.7M | 3.9M | |
Cash | 144.3K | 4.3M | 5.8M | 85.3K | 716.8K | 839.1K | |
Cash And Short Term Investments | 144.3K | 4.3M | 5.9M | 161.1K | 796.1K | 855.2K | |
Common Stock | 19.5K | 24.4K | 28.9K | 32.9K | 7.9K | 7.5K | |
Net Receivables | 640.5K | 999.4K | 1.7M | 1.4M | 759.6K | 625.0K | |
Other Current Assets | 570.4K | 1.7M | 1.9M | 150.2K | 101.1K | 96.0K | |
Non Current Assets Total | 6.0M | 5.4M | 4.1M | 6.9M | 13.3M | 14.0M | |
Non Currrent Assets Other | 179.5K | 164.8K | 160.5K | 1.3M | 1.4M | 1.5M | |
Common Stock Total Equity | 213.7K | 213.9K | 19.5K | 24.4K | 28.1K | 26.7K | |
Accumulated Other Comprehensive Income | 663.8K | 564.9K | 539.7K | 517.1K | 516.4K | 396.8K | |
Net Tangible Assets | (5.7M) | (151.0K) | 3.4M | 8.8M | 10.2M | 10.7M | |
Other Assets | 1.4M | 1.6M | 2.0M | 1.1M | 1.3M | 1.4M | |
Short Long Term Debt | 4.0M | 2.1M | 1.8M | 1.9M | 1.5M | 2.0M | |
Other Liab | 27.5K | 2.9K | 19.3K | 10.6K | 12.2K | 11.0K | |
Short Term Investments | 3.4M | 1.2M | 108.1K | 75.8K | 79.3K | 75.3K | |
Long Term Investments | 3.4M | 1.2M | 932.8K | 842.1K | 2.5M | 1.8M | |
Property Plant Equipment | 510.1K | 1.0M | 2.3M | 2.0M | 2.3M | 2.4M | |
Net Invested Capital | 3.9M | 8.1M | 10.7M | 5.0M | 9.9M | 10.3M | |
Net Working Capital | (5.9M) | 1.3M | 5.9M | (2.8M) | (4.3M) | (4.1M) | |
Capital Stock | 19.5K | 24.4K | 28.9K | 32.9K | 7.9K | 7.5K |
Pair Trading with ABVC Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABVC Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABVC Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ABVC Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABVC Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABVC Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABVC Biopharma to buy it.
The correlation of ABVC Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABVC Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABVC Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ABVC Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for ABVC Stock analysis
When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is ABVC Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.43) | Revenue Per Share 0.035 | Quarterly Revenue Growth (1.00) | Return On Assets (0.43) | Return On Equity (1.92) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.